Thoracic cancer is an umbrella term for any cancer that develops in the chest cavity. This includes cancers of the lungs, esophagus, trachea (windpipe), thymus gland, chest wall, and the lining of the lungs called the pleura. Lung cancer is by far the most common type, but the category also covers rarer malignancies like mesothelioma and thymoma. Because several distinct organs sit within the thoracic cavity, the symptoms, prognosis, and treatment for each type vary considerably.
Types of Thoracic Cancer
The thoracic cavity extends from the base of the neck down to the diaphragm, and any structure within that space can develop cancer. The major types break down as follows:
- Lung cancer is the most common thoracic malignancy and divides into two broad categories: non-small cell lung cancer (NSCLC), which accounts for the majority of cases, and small cell lung cancer (SCLC), a rarer but more aggressive form.
- Esophageal cancer forms in the tube that carries food from your throat to your stomach, which passes through the center of the chest.
- Mesothelioma develops in the thin membrane surrounding the lungs (the pleura) and is strongly linked to asbestos exposure.
- Thymic tumors arise in the thymus, a small organ behind the breastbone that plays a role in the immune system. Thymoma and thymic carcinoma are the two main subtypes.
- Chest wall tumors can develop in the ribs, muscles, or soft tissue of the chest.
Small cell lung cancer, mesothelioma, and thymic tumors are all classified as rare thoracic cancers, but they tend to be aggressive and require specialized treatment planning.
Risk Factors and Causes
Cigarette smoking is the dominant cause of lung cancer, responsible for roughly 85% of cases. Men who smoke are 23% more likely to develop lung cancer compared to people who have never smoked, and women who smoke face a 13% increased risk. Still, most smokers never develop lung cancer, and many people diagnosed have never smoked at all. That gap points to additional factors at work.
Environmental exposures play a significant role. Radon gas, which seeps naturally from the ground into homes, is the second leading cause of lung cancer. Asbestos exposure is the primary risk factor for mesothelioma specifically, often showing up decades after the initial contact. Other environmental risks include heavy metals encountered in industrial smelting, secondhand smoke, air pollution, and exposure to workplace carcinogens.
Genetics matter too. About 8% of lung cancers are thought to be inherited or tied to a genetic predisposition. Having a first-degree relative with lung cancer, especially one diagnosed at a younger age, meaningfully increases your risk. Researchers have identified some contributing genes, but most of the genetic picture remains incomplete. For esophageal cancer, chronic acid reflux and obesity are additional well-established risk factors.
Symptoms and Warning Signs
Thoracic cancers often produce no symptoms in their earliest stages, which is one reason they’re frequently caught late. When symptoms do appear, they depend on where the tumor is located.
For lung cancer, the most common warning signs include a new cough that doesn’t go away, chest pain, coughing up blood (even a small amount), hoarseness, shortness of breath, and wheezing. Esophageal cancer typically presents with difficulty swallowing, unintentional weight loss, and chest pressure. Thymic tumors may cause a persistent cough or chest tightness, and in some cases trigger autoimmune conditions like myasthenia gravis, which causes muscle weakness. Mesothelioma often starts with shortness of breath and pain in the lower chest or rib area.
Many of these symptoms overlap with common, non-cancerous conditions. A cough that lasts more than a few weeks, unexplained weight loss, or any episode of coughing up blood warrants medical evaluation.
How Thoracic Cancer Is Diagnosed
Diagnosis typically begins with imaging. A CT scan of the chest is the standard first step, providing detailed cross-sectional images that can reveal tumors, enlarged lymph nodes, or fluid buildup. PET scans are often used alongside CT to determine whether a suspicious area is metabolically active, which helps distinguish cancer from benign tissue and identify whether the disease has spread.
Confirming a diagnosis requires a biopsy, meaning a small tissue sample is taken and examined under a microscope. There are several ways to obtain that sample. A transthoracic needle biopsy uses CT guidance to insert a needle through the chest wall directly into the suspected area. A transbronchial biopsy reaches tumors through the airways using a flexible scope. Endobronchial ultrasound (EBUS) combines a scope with an ultrasound probe, allowing doctors to sample lymph nodes deep in the chest without open surgery. For tumors that are harder to reach, video-assisted thoracic surgery or newer tools like robotic bronchoscopy and electromagnetic navigation bronchoscopy provide access with greater precision.
Staging and What It Means
Once thoracic cancer is confirmed, staging determines how far it has spread. The TNM system is the standard framework, evaluating three things: the size and extent of the primary tumor (T), whether nearby lymph nodes are involved (N), and whether the cancer has spread to distant sites (M).
For lung cancer, tumor size is classified in 1-centimeter intervals. Tumors up to 3 centimeters fall into the T1 category, with subcategories at each centimeter mark. Tumors larger than 7 centimeters are classified as T4. The metastasis category distinguishes between a single distant site (M1b) and multiple distant sites (M1c), which affects both prognosis and treatment decisions.
Stage at diagnosis has an enormous impact on outcomes. Only 23% of lung cancers are caught while still localized to the lung, but those patients have a 64.7% five-year survival rate. When the cancer has spread to nearby lymph nodes (21% of cases), five-year survival drops to 37.1%. More than half of lung cancers, 52%, are already distant (metastatic) at diagnosis, where five-year survival falls to 9.7%. Overall, the five-year survival rate for lung and bronchus cancer across all stages is 28.1%.
Treatment Options
Treatment depends on the cancer type, stage, and specific molecular characteristics of the tumor. For early-stage lung cancer, surgery to remove part or all of a lung remains the primary approach. Many of these operations are now performed using minimally invasive techniques, including video-assisted or robotic surgery, which typically means shorter hospital stays and faster recovery.
Radiation therapy is used both as a primary treatment for patients who can’t undergo surgery and as a follow-up after surgery to eliminate remaining cancer cells. For locally advanced cancers, radiation is often combined with chemotherapy.
The biggest shift in thoracic cancer treatment over the past decade has been the rise of immunotherapy. Immune checkpoint inhibitors work by removing the brakes that cancer cells place on your immune system, allowing your body to recognize and attack the tumor. These drugs have significantly improved survival for many patients with advanced non-small cell lung cancer and are now being tested in small cell lung cancer and mesothelioma as well.
Targeted therapy is another option for patients whose tumors carry specific genetic mutations. Testing a tumor’s molecular profile has become standard practice because it determines whether certain drugs will be effective. Patients whose cancers carry mutations in genes like EGFR or rearrangements in ALK or ROS1 can receive targeted pills that often work better and cause fewer side effects than traditional chemotherapy.
For small cell lung cancer, which tends to grow and spread quickly, the FDA granted accelerated approval in May 2024 to a new drug called tarlatamab for patients whose cancer has progressed after initial chemotherapy. It received breakthrough and priority review designations, reflecting the urgent need for new options in this aggressive disease.
Screening for Lung Cancer
Because thoracic cancers are so often diagnosed late, screening can make a real difference for people at high risk. The U.S. Preventive Services Task Force recommends annual low-dose CT scans for adults aged 50 to 80 who have a smoking history of 20 pack-years or more and either currently smoke or quit within the past 15 years. A pack-year equals smoking one pack per day for one year, so someone who smoked two packs daily for 10 years would have a 20 pack-year history.
These guidelines were expanded in recent years, lowering the starting age from 55 to 50 and reducing the threshold from 30 to 20 pack-years. The change made millions more people eligible for screening. Low-dose CT catches tumors when they’re small and still localized, which is exactly the stage where survival rates are highest.